BERINERT
- For the treatment of acute abdominal, facial, or laryngeal attacks of hereditary angioedema (HAE) in adult and adolescent patients
- The safety and efficacy of Berinert for prophylactic therapy have not been established.
KALBITOR
- For the treatment of acute attacks of hereditary angioedema (HAE) in patients 12 years of age and older.
FIRAZYR
- For treatment of acute attacks of hereditary angioedema (HAE) in adults 18 years of age and older
RUCONEST
- For the treatment of acute attacks in adult and adolescent patients with hereditary angioedema (HAE)
- Limitation of Use: Effectiveness was not established in HAE patients with laryngeal attacks